Vetter Pharma-Fertigung GmbH & Co. KG Overview
Pro stress-test →Vetter Pharma is a German privately owned Contract Development and Manufacturing Organization (CDMO) specializing in aseptic fill-and-finish manufacturing services for vials, syringes, and cartridges. As a globally leading CDMO for the aseptic production of injectable medications, the company serves innovative pharmaceutical and biotech companies across three continents with state-of-the-art manufacturing capabilities.
Strategic Profile
Pro stress-test →Over 80% of the company's active projects are biologics, positioning Vetter as a specialized partner in the high-growth biologics sector. Founded in Ravensburg in 1950 and remaining family-owned, the company has built decades of manufacturing expertise and regulatory credibility. With production facilities in Germany, Austria, and the US, and sales locations across Asia-Pacific markets including Japan, China, South Korea and Singapore, Vetter operates a globally diversified footprint serving multinational pharma and biotech clients.
Competitive Landscape
Pro stress-test →Vetter Pharma specializes in aseptic fill-and-finish manufacturing for vials, syringes, and cartridges, competing against other large CDMOs such as Catalent, Lonza, Recro Pharma, and West Pharmaceutical Services. The CDMO market is characterized by consolidation, high switching costs, and long customer relationships, with differentiation driven by manufacturing capacity, regulatory compliance, turnaround time, and specialization in high-margin biologic filling. Vetter's private family ownership and focus on quality and sustainability position it as a specialized, customer-centric alternative to larger, publicly traded competitors.
Industry Context
Vetter Pharma-Fertigung GmbH & Co. KG operates in Contract Development and Manufacturing Organization (CDMO) services for aseptic fill-and-finish injectable drugs.
Key facts
Founded: 1950 · Headquarters: Ravensburg, Germany · Employees: 6,590 (2024) · Revenue: €1.114 billion (2024) · Market cap: N/A